Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine

Completed

Conditions studied: Menstrual Migraine

In brief

Post-marketing, retrospective, observational survey study. Users (menstruating women only) of Nerivio who have used Nerivio at least 4 times between October 2019 and December 2020 will be contacted by email and/or through an app notification and will be asked to complete a 5-minute online anonymous survey assessing satisfaction, effectiveness, and safety. Eligible users will sign an informed consent form (the consent language will appear as the first page of the survey, and participants will click either "agree" or "disagree" to the consent statement; those who click "agree" will proceed to the survey, those who click "disagree" will be brought to an exit page) and complete a survey asking about their satisfaction with Nerivio and the effectiveness and safety of the device for acute treatment of menstrual migraine. During the survey, participants will be screened to verify that they have menstrual migraine (self-reported) and have used Nerivio to treat menstrual migraines.

Key facts

Study ID

NCT04600388

Run by

Theranica

People needed

121

Starts

2020-09-09

Expected to finish

2020-11-10

Last updated by the study team

2020-12-04

Who can join

Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women aged 18-55 years
• Participants have used Nerivio at least 4 times
• Participants experience menstrual migraines (pure menstrual migraine or menstrually-related migraine; self-reported)
• Participants have used Nerivio to treat menstrual migraine

You may not qualify if…

• Non-menstruating women

Where it is running

• Vassar Ambulatory Surgical Center — Poughkeepsie, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.